- Home
- CRDL vs ABOS Comparison
CRDL vs ABOS Comparison
Compare CRDL & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- ABOS
- Stock Information
- Founded
- CRDL 2017
- ABOS 1996
- Country
- CRDL Canada
- ABOS United States
- Employees
- CRDL N/A
- ABOS N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- CRDL Health Care
- ABOS Health Care
- Exchange
- CRDL Nasdaq
- ABOS Nasdaq
- Market Cap
- CRDL 80.1M
- ABOS 66.6M
- IPO Year
- CRDL N/A
- ABOS 2021
- Fundamental
- Price
- CRDL $1.15
- ABOS $1.05
- Analyst Decision
- CRDL Strong Buy
- ABOS Strong Buy
- Analyst Count
- CRDL 3
- ABOS 3
- Target Price
- CRDL $9.00
- ABOS $7.33
- AVG Volume (30 Days)
- CRDL 150.5K
- ABOS 217.0K
- Earning Date
- CRDL 05-20-2025
- ABOS 05-13-2025
- Dividend Yield
- CRDL N/A
- ABOS N/A
- EPS Growth
- CRDL N/A
- ABOS N/A
- EPS
- CRDL N/A
- ABOS N/A
- Revenue
- CRDL N/A
- ABOS N/A
- Revenue This Year
- CRDL N/A
- ABOS N/A
- Revenue Next Year
- CRDL N/A
- ABOS N/A
- P/E Ratio
- CRDL N/A
- ABOS N/A
- Revenue Growth
- CRDL N/A
- ABOS N/A
- 52 Week Low
- CRDL $0.77
- ABOS $0.86
- 52 Week High
- CRDL $3.12
- ABOS $3.92
- Technical
- Relative Strength Index (RSI)
- CRDL 57.19
- ABOS 49.09
- Support Level
- CRDL $1.02
- ABOS $0.96
- Resistance Level
- CRDL $1.19
- ABOS $1.13
- Average True Range (ATR)
- CRDL 0.07
- ABOS 0.08
- MACD
- CRDL 0.01
- ABOS 0.01
- Stochastic Oscillator
- CRDL 73.53
- ABOS 46.43
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.